The Pfizer-BioNTech jab has the UK COVID-19[feminine[feminine The vaccination program started on December 8 after receiving emergency approval from the Medicines and Health Products Regulatory Agency (MHRA) less than a week earlier.
January 4, Oxford-AstraZeneca jab also began to be administered after its approval on December 30.
Only one other vaccine has since been approved, but the government has ordered 300 million doses of five more vaccines.
These are the ones that have yet to be deployed or approved:
Approved: Moderna – 17m ordered doses
The Moderna vaccine was approved on January 7 and is expected to be rolled out in April when it ships from the United States.
It is an mRNA vaccine, like the Pfizer vaccine, and trials have shown it to be 95% effective in preventing COVID-19.
Not approved: Novavax – 60m doses ordered
The Novavax vaccine is awaiting approval from the MHRA, which is expected shortly but already made in England.
Novavax, a U.S. vaccine development company that also has facilities in Sweden, began developing a COVID vaccine in January 2020.
This is a protein subunit vaccine that contains the COVID virus spike protein.
In January 2021, its phase three trials found it to be 89.3% effective and offer strong immunity against new variants, including Kent’s.
Its vaccine is manufactured at Fujifilm’s site in Billington, Stockton-on-Tees and will undergo its “fill and finish” at a GlaxoSmithKline (GSK) facility in Barnard Castle, County Durham.
Not approved: Janssen (Johnson & Johnson) – 30m doses ordered
Only one vaccine is needed for this viral vector vaccine – the same kind of technology as that of AstraZeneca.
It was approved in the US in February and in the EU in March after trials found it to be 67% effective in preventing COVID-19 and fully effective in preventing hospitalizations and death from the virus. .
Janssen Pharmaceuticals is a Belgian subsidiary of pharmaceutical giant Johnson & Johnson, so the jab is referred to by both names.
Not approved: Valneva – 100m doses ordered
The French pharmaceutical company’s jab is still being tested, but manufacturing has started at a site in West Lothian, Scotland.
It uses whole inactive viral technology – a dead version of the coronavirus that cannot cause disease but should teach the body’s immune system how to fight it.
If approved, doses of 60 million are expected to be administered in the second half of 2021 and the remaining 40 million next year in case boosters are needed.
Not approved: GlaxoSmithKline / Sanofi Pasteur – 60m ordered doses
The trials were due in December after phase one and two results showed a weak immune response in adults over 49 years old.
They were restarted in February with more volunteers, including older adults, and if the data is positive it could move to advanced stage trials in the second quarter of 2021.
The British drug giant and its French partner, which is the world’s largest all-vaccine company, said a vaccine could be available by the last quarter of 2021.
Not approved: CureVac – 50m doses ordered
An mRNA vaccine, like that of Pfizer and Moderna, the German company is in phase three trials.
He is also working with the UK government and GSK to develop a new variety of vaccine that can protect against several new strains of COVID in one shot.
After phase one trials, the company said its first-generation vaccine closely mimics the immune response after natural infection with COVID-19.
A specialist in RNA technology for 20 years, CureVac joined the UK Vaccines Taskforce in February.
CureVac’s deal with the UK includes the ability to manufacture its vaccines in the UK.